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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease characterized by late diagnosis and treatment resistance.
Recurrent genetic alterations in defined genes in association with perturbations of developmental cell signaling pathways
have been associated with PDAC development and progression. Here, we show that GATA6 contributes to pancreatic
carcinogenesis during the temporal progression of pancreatic intraepithelial neoplasia by virtue of Wnt pathway activation.
GATA6 is recurrently amplified by both quantitative-PCR and fluorescent in-situ hybridization in human pancreatic
intraepithelial neoplasia and in PDAC tissues, and GATA6 copy number is significantly correlated with overall patient
survival. Forced overexpression of GATA6 in cancer cell lines enhanced cell proliferation and colony formation in soft agar in
vitro and growth in vivo, as well as increased Wnt signaling. By contrast siRNA mediated knockdown of GATA6 led to
corresponding decreases in these same parameters. The effects of GATA6 were found to be due to its ability to bind DNA, as
forced overexpression of a DNA-binding mutant of GATA6 had no effects on cell growth in vitro or in vivo, nor did they
affect Wnt signaling levels in these same cells. A microarray analysis revealed the Wnt antagonist Dickopf-1 (DKK1) as a
dysregulated gene in association with GATA6 knockdown, and direct binding of GATA6 to the DKK1 promoter was
confirmed by chromatin immunoprecipitation and electrophoretic mobility shift assays. Transient transfection of GATA6,
but not mutant GATA6, into cancer cell lines led to decreased DKK1 mRNA expression and secretion of DKK1 protein into
culture media. Forced overexpression of DKK1 antagonized the effects of GATA6 on Wnt signaling in pancreatic cancer cells.
These findings illustrate that one mechanism by which GATA6 promotes pancreatic carcinogenesis is by virtue of its
activation of canonical Wnt signaling via regulation of DKK1.
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Introduction
GATA6 is a member of the GATA transcription factor family
that plays critical regulatory roles in tissue development [1].
GATA proteins share a conserved zinc finger sequence that binds
to the canonical DNA motif (G/A)GATA(A/T) [2] and are
divided into two subgroups based on spatial and temporal
expression patterns. GATA1/2/3 are expressed in hematopoietic
cell lineages, and GATA4/5/6 in mesoderm and endoderm
derived organs [1,3]. GATA6 in particular is essential for the
development of the heart, gastrointestinal tract, pancreas and
other tissues [4,5]. The importance of GATA6 is underscored by
the observation that targeted inactivation of the GATA6 gene in
mice causes early embryonic lethality as a result of a lack of
endoderm differentiation [5-7].
Recurrent copy number gain of GATA6 has recently been
identified in pancreatic duct adenocarcinoma (PDAC) cell lines
and xenografts [8,9]. While its role in PDAC carcinogenesis is
unknown, mounting evidence indicates that GATA6 is associated
with tumorigenesis in a variety of tissue types [10-14]. In ovarian
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tumors, ectopic GATA6 expression is correlated with cell
dedifferentiation [15] whereas in colorectal cancer, GATA6
influences cell proliferation and apoptosis by affecting the
expression of 15-Lipoxygenase-1 that plays a role in p53-
dependent cell arrest [16]. Aberrant GATA6 expression of has
also been implicated in human adrenal tumors as well as in an
alpha/SV40 T-antigen transgenic mouse model that develops
adrenocortical tumors in a gonadotropin-dependent fashion
[17,18]. By contrast, GATA6 has been implicated as a tumor
suppressor gene in astrocytomas [14].
This study sought to clarify the mechanisms by which GATA6
contributes to pancreatic carcinogenesis. We now show that
GATA6 amplification occurs during the late stages of pancreatic
intraepithelial neoplasia, is significantly correlated with patient
outcome, and promotes pancreatic carcinogenesis by activating
the canonical Wnt signaling pathway due to its direct transcrip-
tional repression of the secreted Wnt antagonist Dickkopf-1.
Methods
Ethics Statement
All human tissue samples were collected with approval of the
Johns Hopkins Hospital Institutional Review Board (IRB protocols
# NA_00036610 and NA_00001584) after informed and written
consent. For animal experiments, studies were carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the University of Minnesota
(ACUC protocol # MO09M84). All procedures were performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering.
Cell Lines and Tissues
The A6L, A13A, A10.7 and IMIM-PC2 cell lines were
established in our own laboratories. PK8 and PK9 were from
Dr. Akira Horii (Tohoko University, Sendai, Japan), and HCG-25
from Dr. Tony Hollingsworth (University of Nebraska Medical
Center, Omaha NE). All remaining pancreatic cancer cell lines
used were obtained from the ATCC (Manassas VA). The normal
pancreatic duct epithelial cell lines HPNE and HPDE were
prepared as previously described [19]. The colon cancer cell lines
HCT116 (CTNNB1 mutant), SW480 (APC mutant) and RKO
(APC and CTNNB1 wild type) were provided by Dr. James
Eshleman (Johns Hopkins Medical Institutions, Baltimore MD
USA). All cells were cultured in DMEM (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (FBS), 100
units/ml penicillin, 100 mg/ml streptomycin and 2 mmol/L L-
glutamine at 37uC and 5% CO2.
Human pancreatic tissue samples were obtained from the
Surgical Pathology Department of Johns Hopkins and xenografts
were generously provided by Dr. Scott Kern (Johns Hopkins
Medical Institutions, Baltimore MD USA). All samples were
collected with approval of the Johns Hopkins Hospital Institutional
Review Board.
Lentiviral Constructs
Recombinant lentiviruses expressing GFP downstream of a mock
shRNA or an shRNA specific to GATA6 were created using a three-
virus system as previously described in detail [20,21]. Oligonucle-
otide sequences for GATA6 knockdown were sense, 59-gatccgctgt-
cacaccacaactaccttcaagagaggtagttgtggtgtgacagctttttta-39; and anti-
sense, 59-cgataaaaaagctgtcacaccacaactacctctcttgaaggtagttgtggtgtga-
cagcg-39. Following infection, an aliquot of each cell line (16105)
was analyzed by FACS in the Flow Cytometry Core Facility to
confirm the efficiency of transduction (.95% in all cell lines tested)
by monitoring GFP expression 60 h after transduction.
Plasmid Constructs
The human GATA6 vector pcDNA3.1-GATA6 was a gift from
Dr. Clement Ho (University of Pennsylvania, Philadelphia PA)
and used to create pcDNA3.1-mGATA6 by site directed
mutagenesis (Invitrogen) in which the eight most highly conserved
bases of the zinc-finger motif were deleted [22,23]. Human DKK1
expression vector pCMV-DKK1 and the DKK1 promoter
luciferase reporter pGL3-DKK1 were both generously provided
by Dr. Hirotaka Osada (Aichi Cancer Instititue, Nagoya, Japan).
Stable cell lines were created following our methods previously
reported in detail [8].
In vitro Assays of Cell Growth
Cell proliferation assays were performed using Cell Counting
Kit-8 (Dojindo Molecular Technologies) following the suggested
protocol. Colony formation assays were performed as previously
described [8]. All assays were performed in triplicate.
Cell Cycle Analysis
Flow cytometry was performed on a Becton Dickenson LSR
Benchtop Flow Cytometer (BD Biosciences, San Jose, CA).
Percentages of cells in G0-G1, S, and G2 phase were determined
using CellQuest (BD Biosciences).
Enzyme Linked Immunosorbent Assay
ELISAs were performed using mouse mAb anti-human DKK-1
antibody (Clone 141119) following the manufacturers protocol (R
& D Systems, Inc., Minneapolis, MN, USA). All assays were
performed in triplicate.
Western Blotting
Equal amounts of protein were separated on 15% SDS-
polyacrylamide and transferred onto PVDF membranes (DuPont
NEN, Boston, MA). Membranes were hybridized with a 1:100
dilution of primary antibody (ß-catenin mouse mAb clone E-5 or
GATA6 rabbit pAb clone H-92, Santa Cruz Biotechnology, CA)
followed by horseradish peroxidase (HRP)-linked goat anti-rabbit
IgG and visualized by the enhanced chemiluminescence (ECL)
system (Amersham). Expression of ß-actin was used as an internal
control.
Immunohistochemistry
Immunolabeling was performed following previously reported
methods standard methods [8] using a 1:100 dilution of each
primary antibody for 2 hours at room temperature. The specificity
of antibodies to GATA6 and DKK1 is presented by full-screen
Western blotting in Figure S1.
Gene Expression Microarrays
Total RNA was isolated with an RNeasy kit (Qiagen, Valencia,
CA). Samples were hybridized to Agilent Human 4644K arrays
(Santa Clara, CA) and the raw data analyzed following standard
protocols in the Microarray Core Facility at Johns Hopkins. All data
is MIAME compliant and the raw data files have been deposited in
the MIAME compliant GEO database (accession number GSE27173).
Real Time Quantitative PCR for mRNA Expression
One microgram of RNA per sample was reverse transcribed
into cDNA using SuperScriptTMIII PlatinumH Two-Step qRT-
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PCR Kit (Invitrogen). RT-qPCR analysis was performed using a
7300 Real Time PCR System (Applied Biosystems, CA, USA) for
monitoring of green dye fluorescence (SYBRHGreen, Invitrogen
Inc, CA, USA). Relative fold-changes of gene expression
compared to the housekeeping gene b-actin were determined by
calculation of the 2DDCt. All assays were performed in triplicate.
(Primer sequences are provided in File S1).
GATA6 Copy Number Assays
Genomic DNA copy number of GATA6 was determined as
described previously in detail [8]. Copy numbers of .2.3 were
considered copy number gain to account for polysomy of
chromosome 18q, and because up to 20-fold GATA6 overexpres-
sion may occur in PDACs with even low level copy number gain [8].
Luciferase and TOPFLASH Assays
For TOPFLASH assays, pGL3-OT and pGL3-OF plasmids
were used (kindly provided by Dr. Bert Vogelstein). Relative Wnt
activity was determined by the ratio of luciferase expression from
the pGL3-OT vector divided by that of the pGL3-OF vector as
previously described. For all other luciferase assays, the vector
pRL-TK (Promega) expressing sea pansy luciferase was used as a
control. The pcDNA3.1-empty vector was used to adjust the total
amount of transfected DNA. Luciferase assays were performed
40 hrs after transfection using the Dual-Luciferase-Reporter Assay
System (Promega), and luciferase activity was determined with the
1420 multilabel counter (PerkinElmer life and analysis science,
CT, USA). Firefly luciferase activities were normalized by sea
pansy luciferase activities. All experiments were carried out in
triplicate.
Chromatin Immunoprecipitation Assay (CHIP assay)
ChIP assays were performed using reagents and protocols from
Upstate Biotechnology (Lake Placid, NY) using previously
described methods [24]. All primers used were designed to
specifically target GATA binding motifs in the DKK1 promoter.
(Probe sequences are provided in File S1).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA assays were performed using previously described methods
[24]. Protein Extracts were normalized for total protein, and 5–
10 mg of protein were incubated with the 32P-labeled high-affinity
GATA6 probes specific to each of the four putative GATA binding
motifs within the DKK1 promoter. Mutant probes in which the
binding motif sequence was mutated were also used. A GATA6-P
probe (59-GCCAGCAGATAGCATGGAAAAG-39) derived from
TFF2 promoter containing a GATA6 binding site [25] was used as a
positive control. Protein-DNA complexes were resolved on 5%
nondenaturating polyacrylamide gels and analyzed by autoradiog-
raphy using Kodak film. (Probe sequences are provided in File S1).
shRNA Mediated Knockdown
Cultured cells in log phase growth (50% confluent) were
transfected with DKK1 shRNA (Dharmacon), CTNNB1 shRNA
(CTNNB1-VHS50819, Invitrogen Inc, CA) or mock shRNA
(#4611, Ambion) using Lipofectamine RNAiMAX (Invitrogen
Inc, CA) following the recommended protocol. Twenty-four hours
after transfection, cells were harvested and subjected to RT-qPCR
analysis, cell proliferation and colony formation assays.
Flourescent in situ hybridization (FISH)
FISH was performed as described previously [8] using bacterial
artificial chromosome clones CTD-2376C8 containing the geno-
mic sequences of the 18q11.2 amplicon at 0.11 Mb (Invitrogen,
Carlsbad, CA).
Methylation Specific PCR
Promoter methylation was assessed using primers and condi-
tions previously reported by Suzuki et al [26].
Statistical analysis
Statistical analyses were performed with an unpaired t-test for
parametric distributions, or a Chi-squared test for comparing
frequencies. P,0.05 was considered statistically significant.
Results
GATA6 Copy Number Gain Occurs during Pancreatic
Intraepithelial Neoplasia
Normal pancreatic ductal epithelium is believed to progress to
infiltrating cancer through a series of morphologically defined
precursors called pancreatic intraepithelial neoplasia (PanIN-1, 2,
3) [27]. To understand the correlation between genetic gain of
GATA6 and PDAC development, we assessed GATA6 copy
number in microdissected samples of normal duct epithelium,
PanIN, and human PDAC by quantitative PCR. Relative to the
haploid genome, there was no gain of GATA6 in normal duct
epithelium (0 of 4), PanIN-1 (0 of 13) or PanIN-2 (0 of 10) lesions.
By contrast, increased GATA6 copy number ($2.3 copies) was
identified in 6/17 samples (35%) of PanIN-3 and in 18/55 samples
(33%) of PDAC (Figure 1A). GATA6 copy number gain was
further confirmed by fluorescent in situ hybridization (FISH) in
paraffin-embedded sections of one PanIN-3 and 10 PDAC
samples (Figure 1B).
For six patients the matched PanIN-3 and PDAC were
microdissected from the same tissue section and analyzed for
GATA6 copy number, KRAS and TP53 gene status (Table 1). In
two patients (patients 7 and 53) GATA6 copy number gain was
found in both the PanIN-3 and PDAC samples indicating it arose
prior to the development of infiltrating carcinoma, whereas in a
third patient (patient 53) GATA6 copy number gain was only
present within the PDAC sample suggesting it arose during
temporal progression to PDAC. However, as a single PanIN-3 was
analyzed in this patient, we cannot rule that additional and
untested PanIN-3 lesions in this patient’s pancreas also contained
copy number gain. To confirm that increases in GATA6 copy
number result in increased gene expression, we quantified GATA6
mRNA levels in these same microdissected samples (Figure 1C),
indicating that relative levels of GATA6 mRNA were significantly
greater in samples with GATA6 copy numbers $2.3 compared to
those with copy numbers ,2.3 (461.96126.2 and 194.1669.7,
p,0.0004). Similarly, immunolabeling for GATA6 in five
pancreatic cancers with copy number gain showed strong positive
nuclear labeling whereas no labeling was seen in five pancreatic
cancers with copy numbers ,2.3 (Figure 1D).
Pancreatic carcinogenesis is accompanied by the accumulation
of genetic alterations in the KRAS, CDKN2A, TP53 and SMAD4
genes [27]. We therefore determined the relationship of GATA6
copy number gain to the genetic status of these four genes in 56
xenograft enriched PDACs. Seventeen xenografts (30%) had a
GATA6 copy number $2.3 relative to the haploid genome, of
which six (11%) had a copy number .5.0. However, there was no
correlation of KRAS, CDKN2A, TP53 or SMAD4 status with GATA6
copy number. Because GATA6 is also located on the same
chromosome arm as SMAD4 that is frequently targeted by
homozygous deletion [28], we next wondered if GATA6 copy
number gain is specifically related to genomic rearrangement
GATA6 Activates Wnt Signaling in Pancreatic Cancer
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events that may lead to homozygous deletion of SMAD4 in the
same xenograft DNA. However, this again did not reveal an
association, with six of eight SMAD4 mutants occurring due to
homozygous deletion in xenografts with increased GATA6 copy
number versus 13 of 21 with a homozygous deletion in the
xenografts without GATA6 copy number gain (p= 0.2844). Taken
together, we conclude that GATA6 copy numbe$r gain occurs
during late stages of pancreatic intraepithelial neoplasia but is not
specifically enriched for within carcinomas with alterations of these
four genes.
We next determined the extent to which GATA6 copy number
gain is associated with clinicopathologic features of resected
PDAC. No relationships were found for GATA6 and age, gender,
tumor size, tumor differentiation, tumor location or lymph node
status. However, patients with copy number $2.3 had a longer
overall survival than patients without copy number gain by
Kaplan Meier survival estimate (p = 0.0096, Figure 1E).
GATA6 Promotes Cell Growth In Vitro and In Vivo
Amplification and overexpression of GATA6 in PanIN and
PDAC suggests it contributes to PDAC biology [8,9]. We therefore
constructed lentiviral vectors that express either a mock or GATA6
specific shRNA and used them to stably infect the PDAC cell lines
AsPC1 and A13A with copy numbers of 2.3 and 9.0 relative to the
Table 1. Genetic Features of Matched Pancreatic
Intraepithelial Neoplasia and Cancer Samples.
Patient Histology
GATA6 Copy
Number KRAS TP53
7 PanIN-3 5.3 G12R R248W
PDAC 5.1 G12R R248W
10 PanIN-3 3.11 G12V 13 bp del 288
PanIN-3 2.75 G12V 13 bp del 288
PDAC 0.88 G12V 13 bp del 288
53 PanIN-3 4.72 nda G245S
PDAC 3.82 nda nda
58 PanIN-3 0.81 G12D 1 bp insert 255
PDAC 2.38 G12D 1 bp insert 255
64 PanIN-3 1.36 G12D WT
PDAC 1.04 G12D WT
68 PanIN-3 1.14 G12V WT
PDAC 1.16 G12V WT
aNot determined.
doi:10.1371/journal.pone.0022129.t001
Figure 1. GATA6 Copy Number Gain Correlates with Intraductal Progression of Pancreatic Cancer. (A) GATA6 copy number (mean 6 SE)
in microdissected normal ducts (N = 4), PanIN-1 (N = 13), PanIN-2 (10), PanIN-3 (N = 17) lesions and pancreatic cancer (N = 55). (B) Representative FISH
of the nucleus of a neoplastic cell within a PanIN3 lesion with .11-fold GATA6 amplification (right) compared to the nucleus of a neoplastic cell from
a different PanIN3 lesion without copy number gain of GATA6 (left). GATA6 probe was labeled with red and chromosome 18 centromere probe (18
Cent) was labeled with green. The sections were counterstained with DAPI to highlight nuclei. (C) Correlation of GATA6 mRNA expression and copy
number in microdissected samples of normal, PanIN and cancer tissue. (D) GATA6 immunolabeling of two pancreatic cancer tissues with GATA6 copy
number gain compared to two cancers without copy number gain. Increased copy number is highly associated with nuclear labeling of GATA6
protein. (E) Kaplan Meier survival curve illustrating the relationship of GATA6 copy number gain ($2.3 copies per haploid genome) to overall survival
in patients with surgically resected pancreatic cancer.
doi:10.1371/journal.pone.0022129.g001
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haploid genome, respectively [8,9]. In both cell lines, GATA6 is also
overexpressed at least 10-fold relative to normal duct cells [8,9]
(Figure S2). Knockdown of GATA6 in both cell lines (Figure 2A,
2B) led to significant decreases in cell proliferation and colony
formation (Figure 2C and D), a reduction in cells within G2/M
phase (Figure 2E) and decreased growth in vivo (Figure 2F and 2G).
Conversely, forced overexpression of GATA6 in the PDAC cell line
Panc1 with low levels of endogenous GATA6 expression [8]
(Figure 3A and Figure S2) led to increased cell proliferation and
colony formation (Figure 3B and 3C) similar to that also previously
shown for the cell line MiaPaca2 that does not have endogenous
expression of GATA6 [8].
GATA6 regulates DNA transcription by binding to canonical
GATA motifs, or as a transcriptional cofactor [2,29]. To
determine if the effects in Panc1 cells were due to GATA6 DNA
binding activity, we used site-directed mutagenesis to create a
mutant cDNA in which the GATA6 Zn finger domain was
disrupted (called mGATA6), and again stably transfected Panc1
cells (Figure 3A). There was no difference in cell growth or colony
formation among Panc1-mGATA6 cells and Panc1-control
transfected cells (Figure 3B and 3C) suggesting that the growth
promoting effects of GATA6 observed in vitro are due to its
function as a transcription factor. To further clarify the growth-
promoting effect of GATA6, nude mice were inoculated
subcutaneously with Panc1-GATA6 or Panc1-mGATA6 cells.
After 8 weeks, the mean tumor volume was significantly larger in
mice injected with Panc1-GATA6 cells than with Panc1-
mGATA6 cells (Figure 3D and 3E), leading us to conclude that
GATA6 promotes carcinogenesis via its ability to bind DNA.
The Wnt Antagonist Dickkopf1 (DKK1) is a GATA6 Target
Gene
GATA proteins are linked to Wnt signaling in embryogenesis of
the heart and lungs [4,30,31]. We therefore hypothesized that
GATA6 contributes to pancreatic carcinogenesis in part through
its effects on Wnt signaling, a putative relationship that has not
been explored in any detail for this tumor type. Compared to
mock shRNA lentiviral-infected cells, both AsPC1-GATA6sh and
A13A-GATA6sh cells showed a significant decrease in functional
Wnt signaling activity by TOPFLASH assay (Figure 4A) whereas
overexpression of GATA6 in Panc1 and HPNE cells promoted
Wnt signaling activity (Figure 4B). To determine if ß-catenin
expression is required for these effects we silenced ß-catenin
expression using an shRNA strategy in Panc1-GATA6 cells,
leading to a significant inhibition of cell proliferation and colony
formation (Figure 4C and 4D). In pancreatic cancer tissues,
GATA6 overexpression was significantly correlated with nuclear
accumulation of ß-catenin protein (8/12 PDACs with GATA6
overexpression showing ß-catenin nuclear accumulation versus 3/
20 without GATA6 overexpression, p= 0.004) (Figure 4E). Thus,
GATA6 overexpression in PDAC contributes to cell proliferation
and colony formation by enhancing canonical Wnt signaling.
Figure 2. Effects of GATA6 Knockdown on Cell Growth in vitro and in vivo. (A) Total protein was extracted from AsPC1-GATA6sh and A13A-
GATA6sh cells and mock shRNA controls and analyzed by Western blot for relative levels of GATA6 protein relative to actin. (B) Real-time PCR for
GATA6 expression in AsPC1-GATA6sh and A13A-GATA6sh cells. (C) These cells were also analyzed for cell proliferation at different time points, (D)
cultured in soft agar and the number of colonies at 2 weeks counted, and (E) analyzed by flow cytometry to determine the percent of cells in G2/M
phase. (F) Representative xenograft formation in vivo (above) and after explantation (lower) of AsPC1 control and GATA6sh cells at 8 weeks
postinjection. (G) Average tumor volume (mean 6 SE) of these same xenografts at 8 weeks postinjection. Similar results were noted for A13A-
GATA6sh cells (data not shown). With exception of flow cytometry that was performed in duplicate, all experimental data shown represents the
summary three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0022129.g002
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GATA6 regulates its target genes through binding to the
GATA-binding motif [2]. To identify GATA6 target genes that
may influence Wnt signaling, we performed gene expression
profiling using AsPC1-GATA6sh and A13A-GATA6sh and their
mock controls and identified 113 commonly dysregulated genes
(Figure 5A and Table S1) one of which was Dickkopf-1 (DKK1), an
antagonist of canonical Wnt signaling [32]. Wnt11, a known
GATA6 target gene [30], was also identified suggesting that
GATA6 contributes to Wnt pathway regulation in part through
regulation of these genes. Because DKK1 has not previously been
recognized as a GATA6 target gene we specifically focused on the
relationship of GATA6 to DKK1.
Real-time PCR confirmed DKK1 mRNA upregulation and
increased secretion of DKK1 protein into cell media in both cell
lines in the presence of GATA6 knockdown (Figures 5B and 5C).
To determine if DKK1 is a direct target of GATA6, we searched
the DKK1 promoter for GATA6 consensus binding sequences.
Four independent GATA-binding motifs were identified (Figure
S3), and by chromatin immunoprecipitation assay direct binding
of GATA6 to these motifs within the DKK1 promoter was
demonstrated (Figure 5D). Binding by GATA6 was also confirmed
by electrophoretic mobility shift assay (Figure 5E and data not
shown). We next used a luciferase reporter under control of the
DKK1 promoter to determine if GATA6 binding to DKK1 impacts
upon transcriptional activity from the gene. This reporter was
activated in both 293T and Panc1 cells reflecting endogenous
activation of DKK1 expression. However, upon forced GATA6
expression (Fig. 5F) luciferase activity was significantly decreased,
whereas no effect on DKK1 promoter activity was seen in the
presence of the GATA6 binding motif mutant (mGATA6),
indicating that the repressive effects of GATA6 on DKK1 requires
direct binding of GATA6 to the DKK1 promoter. Forced
expression of wild-type but not mGATA6 protein in Panc1 also
led to significant decreases in DKK1 mRNA levels (Figure 5G).
Taken together, these data indicate that GATA6 negatively
regulates DKK1 transcription through direct binding to the
GATA motif in the DKK1 promoter region.
DKK1 Expression in PDAC Correlates with Wnt Activation
Members of the DKK family (DKK1, DKK2, DKK3 and
DKK4) are secreted proteins that inhibit canonical Wnt signaling
by binding to a subunit of the Wnt receptor complex LRP5/6
[32]. Real-time PCR indicated that DKK1 was the only member
of the DKK family that was expressed in both normal duct cell
Figure 3. Effects of GATA6 Overexpression on Cell Growth in vitro and in vivo. (A) Real-time PCR for GATA6 expression in Panc1-mock,
Panc1-GATA6 and Panc1-mGATA6 cells. (B) Panc1-mock, Panc1-GATA6 and Panc1-mGATA6 cells were either analyzed for cell proliferation or (C)
cultured in soft agar and the number of colonies at 2 weeks counted. (D) Representative xenograft formation in vivo (above) and after explantation
(lower) of Panc1-mock, Panc1-GATA6 and Panc1-mGATA6 cells at 8 weeks postinjection. (E) Average tumor volume (mean 6 SE) of these same
xenografts at 8 weeks postinjection. All experimental data shown represents the summary three independent experiments. *, p,0.05; **, p,0.01;
***, p,0.001.
doi:10.1371/journal.pone.0022129.g003
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lines and in the majority of PDAC cell lines analyzed (Figure S4A).
Immunohistochemical labeling for DKK1 showed at least focal
labeling in 27/32 (84%) PDAC tissues (Figure 6A), although in
only 3 cases was strong intensity labeling seen. DKK1 showed low
levels of expression in the 12 PDAC tissues with GATA6
overexpression consistent with GATA6 repression. However,
DKK1 was only overexpressed in 3/20 PDAC tissues without
GATA6 expression, suggesting cellular mechanisms in addition to
GATA6 may repress DKK1 expression in PDAC. Therefore, to
determine if epigenetic silencing plays a role in DKK1 expression
we performed methylation specific PCR of the DKK1 promoter
region (Figure S4B). Five of seven PDAC cell lines with low levels
of DKK1 mRNA expression had promoter methylation of DKK1,
and four of these five also expressed low levels of GATA6,
confirming the possibility that DKK1 epigenetic silencing occurs
in a subset of PDACs that do not overexpress GATA6 as described
for other tumor types [26,33].
To determine the extent to which DKK1 expression affects
canonical Wnt signaling in pancreatic cancer, we silenced DKK1
expression in Panc1, Hs766t and A10.7 cells with high endogenous
levels of DKK1 expression (Figures S4A and S5A). DKK1
knockdown significantly enhanced the activity of a TOPFLASH
reporter (Figure 6B) and promoted cell proliferation (Figure S5B).
By contrast, forced overexpression of DKK1 in Panc 4.14 cells
displaying high OT/OF activity and lacking endogenous DKK1
expression (Figures S4A and S5C) led to significantly decreased
TOPFLASH reporter activity (Figure 6C), and significant reduc-
tions in colony formation (Figure 6D) suggesting that loss of DKK1
expression promotes human PDAC carcinogenesis through activa-
tion of canonical Wnt signaling. Because GATA6 is a direct
transcriptional repressor of DKK1 (Figure 5), we determined if Wnt
signaling activation by GATA6 is specifically mediated by DKK1.
Accordingly, forced co-expression of DKK1 in Panc1-GATA6 cells
blocked the effects of GATA6 compared to Panc1-GATA6 cells
challenged with a control vector (Figure 6E and 6F).
Discussion
Pancreatic ductal adenocarcinoma is a genetically complex
disease characterized by the accumulation of genetic alterations
and by extensive genomic and transcriptomic alterations leading to
cell cycle deregulation, cell survival, invasion and metastasis [34].
We now provide compelling evidence that GATA6 copy number
gain is an additional and recurrent genetic alteration to be
considered for this tumor type, and contributes oncogenic signals
by virtue of its enhancement of Wnt signaling.
Although Wnt signaling is aberrantly activated in PDAC
[35,36], mutations of CTNNB1, APC or other pathway compo-
nents are rare in this tumor type suggesting alternative
mechanisms for Wnt activation. At least two additional pathways
Figure 4. GATA6 Overexpression Correlates with Canonical Wnt Signaling. (A) Wnt signaling activity in AsPC1-GATA6sh and A13A-
GATA6sh cells based on TOPFLASH assay. Luciferase activity is represented as the ratio of OT to OF levels in cells with GATA6 knockdown relative to
that of mock-transfected cells. (B) Wnt signaling activity in Panc1-GATA6 and HPNE-GATA6 cells determined by TOPFLASH assay. Luciferase activity is
represented as the ratio of OT to OF levels in GATA6 transfected cells relative to that of mock-transfected cells. (C and D) Panc1-GATA6 cells were
transiently transfected with ß-catenin or mock shRNA and (C) cell proliferation or (D) colony formation determined. All experimental data shown
represents the summary three independent experiments. *, p,0.05; **, p,0.01. (E) Immunolabeling patterns of GATA6 and ß-catenin protein in two
representative PDAC tissues. Arrows indicate nuclear labeling of both GATA6 and ß-catenin in serial sections of the same cancer tissue. By contrast,
the PDAC sample with low GATA6 expression also shows no expression of ß-catenin.
doi:10.1371/journal.pone.0022129.g004
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known to be active in PDAC have also been reported as
converging on the Wnt pathway [37,38]. For example, a recent
study has reported that ataxia-telangiectasia group D comple-
menting gene (ATDC) has oncogenic potential through stabilizing
ß-catenin and activating the Wnt pathway in PDAC [38] whereas
in a mouse model of pancreatic carcinoma activation of Hedgehog
signaling led to a corresponding activation of Wnt signaling in part
due to upregulation of TCF4 expression [37]. This is consistent
with our data as well as we demonstrate Wnt pathway activation
due to transcriptional repression by GATA6 of the secreted Wnt
antagonist DKK1. At the very least, the upregulation of Wnt
activity mediated by GATA6 dependent repression of DKK1
further supports the view that GATA6 is an oncogene in
pancreatic ductal adenocarcinoma.
Although GATA6 amplification has been reported in pancreatic
cancer cell lines and xenografts [8,9], when GATA6 amplification
occurs during the step-wise progression of pancreatic intraepithe-
lial neoplasia has not. We now show that GATA6 amplification
occurs during the late stages of pancreatic intraepithelial neoplasia,
specifically PanIN-3. Amplification lead to increased expression in
these same lesions, and parallels prior observations GATA6
protein overexpression in pancreatic intraepithelial neoplasia and
cancer [8,9]. Perhaps the most important implication of this
finding is that detectable GATA6 copy number gain may have
value as a diagnostic marker of PDAC while still in the curative
stage, as this remains a critical hurdle to improving survival of this
disease [39]. However, as genetic gain of GATA6 was only
identified in a third of samples, a more universal and sensitive
Figure 5. DKK1 is a GATA6 target gene. (A) Venn diagram indicating the number of dysregulated genes identified by microarray analysis of
AsPC1-GATA6sh (left circle, blue) and A13A-GATA6sh cells (right circle, yellow). The green cross-area indicates commonly dysregulated genes and
includes DKK1. (B) Real-time PCR confirming DKK1 overexpression in AsPC1-GATA6sh and A13A-GATA6sh cells. (C) Detection of secreted DKK1
protein in conditioned media in AsPC1-GATA6sh and A13A-GATA6sh cells. Secreted DKK1 protein levels are indicated by using absorbance OD450.
(D) Chromatin immunoprecipitation assay confirming binding of GATA6 to the DKK1 promoter. Non-immune IgG and whole genome derived gDNA
are used as negative and positive controls, respectively. (E) EMSA assay confirming binding of GATA6 to putative GATA binding sites #2 and#3. The
mutant sequence mGATA-#3 did not generate any detectable binding. Nuclear Extr, nuclear extract; GATA6-P, a positive control probe derived from
the TFF2 promoter containing a GATA6 binding site; GATA-#2, probe containing putative GATA binding site No. 2; GATA-#3, probe containing
putative GATA binding site No. 3; mGATA-#3, probe containing a mutated putative GATA binding site No. 3; refer to methods for additional details
(F) Effect of GATA6 expression on activity of the DKK1 promoter. Data is presented as the ratio of firefly luciferase activity to sea pansy luciferase
activity. pGL3 was used as a negative control for background. (G) Real-time PCR for DKK1 mRNA expression in Panc1 cells. When appropriate, all
experimental data shown represents the summary three independent experiments. *, p,0.05; ***, p,0.001.
doi:10.1371/journal.pone.0022129.g005
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marker of canonical Wnt signaling dysregulation may be of value
for this purpose.
We also noted a significant relationship among GATA6 copy
number and overall survival, in that patients whose resected
cancers had a copy number $2.3, or nuclear overexpression, had
a longer overall survival than those patients without copy number
gain. Although the biologic significance of this finding remains to
be discerned, it is conceivable that PDACs with high GATA6 copy
number, and/or simply with active canonical Wnt signaling for
which GATA6 copy number is a marker, cosegregate with those
PDACs with less aggressive features as we have recently shown for
E-cadherin [40]. It is also important to note that proliferative rates
alone do not fully represent aggressive biology (metastasis), an
interpretation that is in keeping with our published data that
pancreatic cancers with low metastatic ability (,10 metastases at
autopsy) are actually larger at diagnosis, are more invasive into
surrounding tissues than those with highly metastatic ability, yet
are often associated with a longer overall survival [41]. In addition
to its role in Wnt signaling, ß-catenin is also a critical component
of the adherens junction complex that includes E-cadherin, p120,
plakoglobin and c-catenin. Binding of ß-catenin to c-catenin links
the adherens junction complex to the actin cytoskeleton, thereby
providing mechanical stability [42], whereas disruption of this
complex is associated with epithelial-mesenchymal transition and
aggressive features in a variety of tumor types, including PDAC
[43]. One interpretation is that the presence of canonical Wnt
pathway activity together with an intact zona-adherens in PDAC,
both that are dependent on ß-catenin expression, may be linked to
less aggressive features than when ß-catenin expression is lost [40].
DKK1 belongs to the Dickkopf family comprised of four
members that include DKK2, DKK3 and DKK4. With exception
of DKK3, all members have the ability to modulate Wnt signaling
through inhibiting the Wnt co-receptor LRP5/6 at the cell surface
leading to destabilization of ß-catenin and its subsequent
degradation [44]. Quantitative analysis indicated that DKK1
was the predominant member of this gene family expressed in
PDAC cell lines, consistent with Takahashi et al [45]. Although
that study did suggest DKK1 upregulation functions as an
oncogene in PDAC cells, it is important to note that only Suit-2
and a related cell line were used in that study that was not used in
the current work, and the levels of GATA6 in Suit-2 are unknown.
By contrast, our data has relied on multiple cell lines selected
based on GATA6 and DKK1 expression levels and Wnt signaling
levels. Therefore it is conceivable that the conclusions drawn based
Figure 6. DKK1 Mediates GATA6 Effects on Wnt Signaling. (A) Representative DKK1 and ß-catenin immunolabeling in two human pancreatic
cancer tissues. Arrows in the bottom left panel indicate location of cancer cells with negative labeling for ß-catenin (all images x400) (B) Panc1, A10.7
and Hs766t cells were transfected with a shRNA against DKK1 and subjected to TOPFLASH assay. Wnt activities are presented as a ratio of OT activity
to OF activity. (C and D) Panc 4.14 cells were transfected with a DKK1-expressing vector and subjected to (C) TOPFLASH assay or (D) cultured in soft
agar and the number of colonies at 2 weeks counted. Panc1 cells were transfected with mock, GATA6, and/or DKK1 expressing vectors, and cells were
analyzed for (E) cell proliferation, or (F) cultured in soft agar and number of colonies at two weeks counted. When appropriate, all experimental data
shown represents the summary three independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0022129.g006
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use of the Suit-2 cell line, while valid, are not fully representative of
DKK1 regulation in PDAC.
In summary, GATA6 contributes to PDAC through activation of
the canonical Wnt signaling pathway. This finding expands upon
recent observations of GATA6 amplification, and provides fertile
ground for additional studies of the role of GATA transcription
factors and Wnt signaling in this pathogenesis and aggressiveness
of this tumor type.
Supporting Information
Figure S1 Western Blotting for GATA6 and DKK1 in
Pancreatic Cancer Cell Lines. The specificity of antibodies
against GATA6 and DKK1 is shown by full-screen Western
blotting. Exposures of both 2 and 5 minutes are shown.
(TIF)
Figure S2 RT-PCR for GATA6 expression in human
normal and pancreatic cancer cell lines. b-actin is used as a
loading control for each sample.
(TIF)
Figure S3 Structure of the human DKK1 promoter
region. The human DKK1 promoter has a TATA box near the
transcription site (TSS) and four GATA binding motif within 1 kb
upstream from TSS. *, putative GATA binding site No. 1
(reverse); #, putative GATA binding site No. 2 (forward); m,
putative GATA binding site No. 3 (forward); ¢, putative GATA
binding site No. 4 (reverse). TATA box is enclosed by box.
Sequences for the primer sets that be used in CHIP assay were
indicated in bold type. TSS, transcription start site; Primer F1
(forward) and R1 (reverse) for amplifying the region containing
three GATA binding motifs No. 1, 2 and 3. Primer F2 (forward)
and R2 (reverse) for amplifying the region containing one GATA
binding motif No. 4. The same region also contains four TCF-
binding sites: TBE1, TBE2, TBE3 and TBE4.
(TIF)
Figure S4 Expression and Methylation of Dickkopf-1 in
Pancreatic Cancer Cell Lines. (a) Quantitative RT-PCR of
DKK1-4 in immortalized normal and pancreatic cancer cell lines.
All values are normalized to levels in HPNE. (b) Promoter
methylation of DKK1 in immortalized normal and pancreatic
cancer cell lines.Methylation is detected in cell lines MiaPaca2,
Hs766t, Panc 4.14, PK8 and PK9. All primer sequences are
provided in Supplemental Information.
(TIF)
Figure S5 Effect of Dickkopf-1 on cell proliferation in
Pancreatic Cancer Cell Lines. Panc1, A10.7 and Hs766t cell
lines that have relatively high DKK1 expression levels were
transfected with a mock siRNA or DKK1 siRNA and then
subjected to (A) real-time PCR for DKK1 expression in DKK1-
knock down cells or (B) cell proliferation assays. (C) Real-time
PCR for DKK1 expression in Panc 4.14 cells after transfection
with a mock or DKK1 expression vector. When appropriate, all
experimental data shown represents the summary three indepen-
dent experiments. **, p , 0.01; ***, p , 0.001.
(TIF)
Table S1 Genes commonly dysregulated in both A13A-
GATA6sh and AsPC1-GATA6sh cells. A13A and AsPC1 cells
were infected with a lentivirus expressing a mock shRNA or
shRNA against GATA6 and subjected to cDNA microarray assay.
Microarray data was analyzed using GeneChip analysis software.
All mRNA transcripts was calculated for the GATA6-knock down
samples and compared with mock control. Genes that were
commonly desregulated in both A13A and AsPC1 cells are shown.
Data deposited in the GEO database (number GSE27173).
(DOC)
File S1 Oligonucleotide Sequences Used in Current
Study.
(DOC)
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